VIVANI MEDICAL, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.65 USD | +1.23% |
|
-11.41% | +59.80% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 91.81M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.34
x | P/E ratio 2025 * |
-2.98
x | Employees | 36 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.60% | ||
| 1 week | -11.41% | ||
| Current month | +0.62% | ||
| 3 months | +61.39% | ||
| 6 months | +71.58% | ||
| Current year | +59.80% |
1 week
1.62
1.84
1 month
1.612.01
Current year
1.007.80
1 year
0.847.80
3 years
0.757.80
5 years
0.757.80
10 years
0.757.80
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Mendelsohn
FOU | Founder | 42 | 03-05-21 |
Brigid Makes
DFI | Director of Finance/CFO | 68 | 22-08-29 |
Truc Le
COO | Chief Operating Officer | 71 | 22-08-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Williams
CHM | Chairman | 65 | 08-12-31 |
Wilford Baker
BRD | Director/Board Member | 81 | 20-12-31 |
Aaron Mendelsohn
BRD | Director/Board Member | 72 | 97-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 1.63 | -7.39% | 122 896 |
| 24-05-24 | 1.67 | +2.45% | 128,256 |
| 24-05-23 | 1.63 | -7.39% | 122,896 |
| 24-05-22 | 1.76 | -1.40% | 158,791 |
| 24-05-21 | 1.785 | -2.99% | 88,548 |
End-of-day quote Nasdaq, May 22, 2024
More quotes
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Companyâs lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Companyâs implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Calendar
2024-06-02
- Bio International Convention
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.67
USD
Average target price
8
USD
Spread / Average Target
+379.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +59.80% | 91.81M | |
| +12.05% | 128B | |
| -8.59% | 10.9B | |
| -0.49% | 8.69B | |
| +36.99% | 5.48B | |
| +8.02% | 3.43B | |
| -10.32% | 2.76B | |
| -12.70% | 2.05B | |
| -13.26% | 1.93B | |
| -27.86% | 1.67B |
- Stock Market
- Equities
- VANI Stock
